ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Exploration of the Molecular Mechanism of Polygonati Rhizoma in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking

Zhao, Jinlong; Lin, Fangzheng; Liang, Guihong; Han, Yanhong; Xu, Nanjun; Pan, Jianke; Luo, Minghui; Yang, Weiyi*; Zeng, Lingfeng*广州中医药大学
Frontiers in Endocrinology2022-1-5DOI: 10.3389/fendo.2021.815891
8被引19阅读
引用收藏
分享

摘要

ObjectiveTo explore the effective components and mechanism of Polygonati Rhizoma (PR) in the treatment of osteoporosis (OP) based on network pharmacology and molecular docking methods. MethodsThe effective components and predicted targets of PR were obtained through the Traditional Chinese Medicine Systems Pharmacology and Analysis Platform (TCMSP) database. The disease database was used to screen the disease targets of OP. The obtained key targets were uploaded to the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database for protein-protein interaction (PPI) network analysis. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of key targets. Analysis and docking verification of chemical effective drug components and key targets were performed with IGEMDOCK software. ResultsA total of 12 chemically active components, 84 drug target proteins and 84 common targets related to drugs and OP were obtained. Key targets such as JUN, TP53, AKT1, ESR1, MAPK14, AR and CASP3 were identified through PPI network analysis. The results of enrichment analysis showed that the potential core drug components regulate the HIF-1 signaling pathway, PI3K-Akt signaling pathway, estrogen signaling pathway and other pathways by intervening in biological processes such as cell proliferation and apoptosis and estrogen response regulation, with an anti-OP pharmacological role. The results of molecular docking showed that the key targets in the regulatory network have high binding activity to related active components. ConclusionsPR may regulate OP by regulating core target genes, such as JUN, TP53, AKT1, ESR1, AR and CASP3, and acting on multiple key pathways, such as the HIF-1 signaling pathway, PI3K-Akt signaling pathway, and estrogen signaling pathway.

学科与关键词

关键词
Polygonati Rhizomapotential therapeutic targetssignaling pathwaysmolecular mechanismnetwork pharmacologymolecular docking
相关
加载中…
  • Network Pharmacological Study on Mechanism of the Therapeutic Effect of Modified Duhuo Jisheng Decoction in Osteoporosis
    Huang, Xudong; Zhou, Zhou; Zheng, Yingyi; Fan, Guoshuai; Ni, Baihe; Liu, Meichen; Zhao, Minghua; Zeng, Lingfeng*; Wang, Weiguo*Frontiers in Endocrinology, 2022, 13: 860649.被引 2
  • Analysis of Molecular Mechanism of Erxian Decoction in Treating Osteoporosis Based on Formula Optimization Model
    Yang, Lang; Fan, Liuyi; Wang, Kexin; Chen, Yupeng; Liang, Lan; Qin, Xuemei; Lu, Aiping; Cao, Peng; Yu, Bin*; Guan, Daogang*; Peng, Junxiang*Oxidative Medicine and Cellular Longevity, 2021, 2021: 6641838.被引 27
  • Decoding the mechanism of Eleutheroside E in treating osteoporosis via network pharmacological analysis and molecular docking of osteoclast-related genes and gut microbiota
    Zhou, Tianyu; Zhou, Yilin; Ge, Dongdong; Xie, Youhong; Wang, Jiangyan; Tang, Lin; Dong, Qunwei*; Sun, Ping*Frontiers in Endocrinology, 2023, 14: 1257298.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2022-01-05
卷期
第 12 卷
页码
815891
DOI
10.3389/fendo.2021.815891
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82004383, 81974574]; National key research and development program [2021YFC1712804]; Science and Technology Research Project of Guangdong Provincial Hospital of Chinese Medicine [YN2019ML08]; China Postdoctoral Science Foundation [2018M633036]; Medical Scientific Research Foundation of Guangdong Province [B2019091]

作者

  • Z

    Zhao, Jinlong (第一作者)

    2 · guangzhou univ chinese med

  • L

    Lin, Fangzheng

    2 · guangzhou univ chinese med

查看全部 9 位作者收起作者
  • L

    Liang, Guihong

    2 · guangzhou univ chinese med

  • H

    Han, Yanhong

    2 · guangzhou univ chinese med

  • X

    Xu, Nanjun

    2 · guangzhou univ chinese med

  • P

    Pan, Jianke

    2 · guangzhou univ chinese med

  • L

    Luo, Minghui

    2 · guangzhou univ chinese med

  • Y

    Yang, Weiyi (通讯)

    2 · guangzhou univ chinese med

  • Z

    Zeng, Lingfeng (通讯)

    2 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417